ライフサイエンスコーパス: virus-neutralizing antibody

1 (HIV-1(DH12)) developed an extremely potent virus-neutralizing antibody.

2 s, in which it elicited high titers of DEN-2 virus-neutralizing antibody.

3 a complex of the HAstV capsid protein and a virus-neutralizing antibody.

4 e serum samples were negative for anti-Nipah virus neutralizing antibodies.

5 in a delayed production of high affinity and virus neutralizing antibodies.

6 RS((R)) MLV strain, A2MC2-P90 elicits higher virus neutralizing antibodies.

7 ss switch from immunoglobulin M (IgM) to IgG virus-neutralizing antibodies.

8 l epitopes necessary to elicit high-titered, virus-neutralizing antibodies.

9 conformational epitopes important to elicit virus-neutralizing antibodies.

10 tein B that is able to induce high titers of virus-neutralizing antibodies.

11 eted soluble glycoprotein (sGP) that absorbs virus-neutralizing antibodies.

12 virus capsid protein in a complex with three virus-neutralizing antibodies.

13 strovirus capsid protein in complex with two virus-neutralizing antibodies.

14 guinea pigs and capable of eliciting potent virus-neutralizing antibodies.

15 CoV-2 variants in the presence or absence of virus-neutralizing antibodies.

16 nterferon response and delayed production of virus-neutralizing antibodies.

17 unogenic form that elicits highly functional virus-neutralizing antibodies.

18 another through nanotubes in the presence of virus-neutralizing antibodies.

19 structures within gB that are recognized by virus-neutralizing antibodies.

20 uction in the CNS prior to the appearance of virus-neutralizing antibodies.

21 HCMV is a major antigen for the induction of virus-neutralizing antibodies.

22 antibody responses as well as for anti-AD-5 virus-neutralizing antibodies.

23 eading to the production of higher levels of virus-neutralizing antibodies.

24 ith host cell membranes and is recognized by virus-neutralizing antibodies.

25 rhinovirus (RV) infections by production of virus-neutralizing antibodies.

26 olonies and much higher prevalence of rabies virus-neutralizing antibodies.

27 f virion-specific immunoglobulin G (IgG) and virus-neutralizing antibodies.

28 of the INF-gamma gene failed to produce any virus-neutralizing antibodies.

29 Virus-neutralizing antibodies (Abs) coat MMTV virions se

30 moral responses, including the production of virus-neutralizing antibodies (Abs) directed at viral en

31 s the contribution of cellular responses and virus-neutralizing antibodies (Abs) to the control of re

32 red as newborns or as adults as they produce virus-neutralizing antibodies (Abs).

33 munization of the monkeys with L(EV)-induced virus-neutralizing antibodies against EBO-Z caused a sli

34 ciation with zoonosis, the prevalence of the virus-neutralizing antibody against three recovirus sero

35 tween measured levels of serotypes of dengue virus neutralizing antibody and clinical outcomes sugges

36 he presence of GLA-SE induced high titers of virus-neutralizing antibodies and conferred complete lun

37 he SARS-CoV-2 spike is the primary target of virus-neutralizing antibodies and critical to the develo

38 .8% (95% CI, 14.0-24.4) for Jamestown Canyon virus-neutralizing antibodies and from 7.6% (95% CI, 4.2

39 tection correlated with the presence of both virus-neutralizing antibodies and primed CTL in the immu

40 pment of subunit vaccines are able to induce virus-neutralizing antibodies and protective efficacy in

41 with DeltaG-89.6P-RVG developed SHIV(89.6P) virus-neutralizing antibodies and SHIV(89.6P)-specific c

42 s (glycans), some of which are recognized by virus-neutralizing antibodies and some of which protect

43 induce specific adaptive immunity, based on virus-neutralizing antibodies and T cell responses.

44 Detailed characterization of virus-neutralizing antibodies and target epitopes is nee

45 , with serum antibody titers to both measles virus (neutralizing antibody) and HPIV3 (hemagglutinatio

46 es virus-specific binding antibodies, rabies virus neutralizing antibodies, and rabies virus antigens

47 N-003 elicited increases in antigen binding, virus neutralizing antibody, and T-cell responses.

48 e Q508 escape mutation common to a number of virus-neutralizing antibodies, and therefore provides fu

49 oded proteins, and a significant fraction of virus neutralizing antibodies are directed at gB.

50 Mumps virus-neutralizing antibodies are believed to be the mos

51 Although virus-neutralizing antibodies are likely to protect, ant

52 We have shown that during natural infection, virus-neutralizing antibodies are principally directed a

53 e summarize accumulated knowledge on anti-BK virus neutralizing antibodies as well as their clinical

54 ted pigs are delayed onset and low levels of virus neutralizing antibodies, as well as weak cell-medi

55 The presence of virus-neutralizing antibodies at the time of infection w

56 matic mutation pathways by which potent Zika virus-neutralizing antibodies can evolve, including the

57 logical activities, such as the induction of virus-neutralizing antibody, cell-virus fusion, and cell

58 Furthermore, passive transfer of virus-neutralizing antibodies completely compensated for

59 irus vaccine, which generates high levels of virus neutralizing antibodies, confers reduced virus loa

60 Pseudo-particle virus-neutralizing antibodies correlated with total anti

61 Virus control is unrelated to virus-neutralizing antibodies, cytotoxic CD8(+) T cells,

62 aft recipients and infants infected in utero Virus-neutralizing antibodies defined in vitro have been

63 ecipients remained asymptomatic, with rabies virus neutralizing antibodies detected in their serum af

64 The virus neutralizing antibody dilutional titer levels rang

65 Virus-neutralizing antibodies directed against any of th

66 emic H1N1 virus elicited a boost in titer of virus-neutralizing antibodies directed against the hemag

67 a donor with broadly cross-reactive, primary virus-neutralizing antibodies (donor of reference serum,

68 ters and induced very high levels of measles virus neutralizing antibodies (>1:8,000) that are well i

69 Although gp120 can elicit virus-neutralizing antibodies, HIV eludes the immune sys

70 FeLV-specific effector CTLs appeared before virus neutralizing antibodies in cats that recovered fro

71 sally, induced surface glycoprotein-specific virus neutralizing antibodies in serum and immunoglobuli

72 Studying the contribution of anti-BK virus neutralizing antibodies in viral control has long

73 ralization capacity as measured by surrogate virus-neutralizing antibodies in addition to IgG-, IgM-,

74 ded various results on its ability to induce virus-neutralizing antibodies in animal models and human

75 Both antigens elicited specific virus-neutralizing antibodies in immunized mice.

76 raised substantial levels of antipeptide and virus-neutralizing antibodies in sera and of peptide-spe

77 dministered intranasally, induced F-specific virus-neutralizing antibodies in serum and immunoglobuli

78 novirus 5 (AdHu5), is the high prevalence of virus-neutralizing antibodies in the human population.

79 rus-resistant mice control the pathogen with virus-neutralizing antibodies independently of commensal

80 LnJ H2-Ob allele supported the production of virus-neutralizing antibodies independently of the class

81 found a potent anti-simian immunodeficiency virus neutralizing antibody induction associated with a

82 a broad spectrum of responses which includes virus neutralizing antibodies is a desirable goal for le

83 G-, IgM-, and IgA-antibody levels, surrogate virus-neutralizing antibody levels, and antibody avidity

84 We isolated a virus-neutralizing antibody lineage that targeted an env

85 immunized mice developed high-titer vaccinia virus-neutralizing antibodies (mean PRNT50 = 1:3,760).

86 nfection stimulates higher levels of measles-virus-neutralizing antibodies (mnAbs) than does vaccinat

87 redominantly tier 1 and/or autologous tier 2 virus neutralizing antibody (NAb) responses, as well as

88 activated HRV vaccine can be protective, and virus-neutralizing antibodies (nAb) correlated with prot

89 er they confer neurovirulence or escape from virus-neutralizing antibody (nAb) in vivo is unknown.

90 Influenza virus neutralizing antibodies (NAbs) are promising proph

91 However, potent virus neutralizing antibodies (NAbs) can develop during

92 ability of the engineered antigens to elicit virus-neutralizing antibodies (NAbs).

93 ope glycoprotein (Env) that is the target of virus-neutralizing antibodies on the surfaces of virions

94 that animals vaccinated with Mt 10 developed virus-neutralizing antibodies, predominantly containing

95 ed Brucella abortus induces the secretion of virus-neutralizing antibodies, predominantly of the immu

96 infection is complex and is known to include virus-neutralizing antibody production against surface g

97 Despite waning of virus-neutralizing antibodies, protection against severe

98 function of these cells is the production of virus-neutralizing antibodies rather than priming or rea

99 ion at a low multiplicity with wild-type FIX virus, neutralizing antibody reduced the accumulation of

100 A key secondary endpoint was wild-type virus neutralizing antibody response.

101 is associated with the induction of a robust virus-neutralizing antibody response and clearance of th

102 These data indicated that gM/gN can elicit a virus-neutralizing antibody response in humans infected

103 Furthermore, the virus-neutralizing antibody response in wild-type mice c

104 mechanism to control the development of the virus-neutralizing antibody response required for recove

105 -deficient mice correlated with a more rapid virus-neutralizing antibody response than was observed i

106 amma-deficient mice developed an accelerated virus-neutralizing antibody response, they did not class

107 e cells failed to elicit either viremia or a virus-neutralizing antibody response.

108 previous study, the vaccine elicited strong virus neutralizing antibody responses in sheep and was D

109 Yellow fever virus neutralizing antibody responses occurred earlier i

110 lobulin G (IgG) antibody responses and mumps virus-neutralizing antibody responses (based on the focu

111 hMPV-infected cotton rats mounted virus-neutralizing antibody responses and were partially

112 Virus-neutralizing antibody responses did not explain wh

113 rtance of inducing both T cell responses and virus-neutralizing antibody responses for effective retr

114 induced robust antigen-specific binding and virus-neutralizing antibody responses targeting homologo

115 ls and in some cases was also independent of virus-neutralizing antibody responses.

116 Rabies virus neutralizing antibodies (RVNA) titers were assesse

117 viously uninfected individuals boosted serum virus-neutralizing antibodies significantly against not

118 ers of subtype cross-reactive antibodies and virus-neutralizing antibodies specific for the immunizin

119 ed I/LnJ mice are capable of producing IgG2a virus-neutralizing antibodies, sustain this response thr

120 esenting two rabies virus epitopes stimulate virus neutralizing antibody synthesis in immunized mice.

121 antly, however, in the absence of detectable virus-neutralizing antibodies, systemic or lung-resident

122 junction induced about 400-fold more measles virus-neutralizing antibody than did the rPIV3 with the

123 assays that can be used to measure influenza virus-neutralizing antibodies that are not detected in t

124 Here, we observe a 9.5-fold reduction of virus neutralizing antibody titer in vaccinated hamster

125 accination, which correlated positively with virus neutralizing antibody titer, the ability to resist

126 ions that are associated with a reduction in virus neutralizing antibody titer.

127 assessed as percentage of those with rabies virus neutralizing antibodies titers >= 0.5 IU/mL on day

128 assessed as percentage of those with rabies virus neutralizing antibodies titers 0.5 IU/mL on day 14

129 The vaccine elicited high virus neutralizing antibody titers and conferred complet

130 strong correlation was observed between high virus neutralizing antibody titers and protection follow

131 , receptor binding domain, nucleocapsid, and virus neutralizing antibody titers with each other and w

132 prompt and potent stimulation of protective virus neutralizing antibody titers, which are produced i

133 fluid, total anti-IAV IgG and IgA titers and virus-neutralizing antibody titers but not hemagglutinin

134 Serum rabies virus-neutralizing antibody titers sufficed to protect n

135 h nodes and the peripheral blood, and higher virus-neutralizing antibody titers than immunization wit

136 sues of all VLP-inoculated groups, but serum virus-neutralizing antibody titers were not significantl

137 ific immunoglobulin G antibody responses and virus-neutralizing antibody titers.

138 oglobulins nor could they maintain long-term virus-neutralizing antibody titers.

139 nfluenza pandemic possess highly functional, virus-neutralizing antibodies to this uniquely virulent

140 imal is recognized, prompt administration of virus-neutralizing antibodies, together with active immu

141 with wt RABV did not activate DCs, stimulate virus neutralizing antibodies (VNA), or protect recipien

142 ene-deleted RV vaccine induced 4-fold higher virus-neutralizing antibody (VNA) levels in rhesus macaq

143 verexpression of CXCL13 resulted in enhanced virus-neutralizing antibody (VNA) production and protect

144 Furthermore, virus-neutralizing antibody (VNA) titers were significan

145 10 p.i.) production of significant levels of virus-neutralizing antibody (VNA).

146 cation-deficient RABV-based vaccine produced virus neutralizing antibodies (VNAs) within 3 days of va

147 nized with LBNSE-CXCL13 produced more rabies virus-neutralizing antibodies (VNAs) and developed bette

148 l deficiency, we show that B cells secreting virus-neutralizing antibodies (VNAs) are induced via T c

149 long-lived PCs, it also generated prolonged virus-neutralizing antibodies (VNAs), resulting in bette

150 Similarly, influenza-specific virus-neutralizing antibody was generated and maintained

151 Measles virus neutralizing antibodies were also measured by in v

152 ere, we report that cross-reactive monkeypox virus neutralizing antibodies were detectable in only a

153 generated by each of the three vaccines, but virus-neutralizing antibodies were detected only in mice

154 genes and functional IFN-gamma genes because virus-neutralizing antibodies were still generated, cons

155 at recombinant trimers may be able to elicit virus-neutralizing antibodies when delivered as immunoge

156 at recombinant trimers may be able to elicit virus-neutralizing antibodies when delivered as immunoge

157 epitopes primed for more rapid production of virus-neutralizing antibody which appeared to limit viru

158 The emerging class of glycan-reactive virus-neutralizing antibodies with exceptional breadth o

159 CI 21,617 to 36,623) EU/mL and for wild-type virus neutralizing antibody (with an inhibitory concentr

160 aled that LNPs induced high titers of Dengue virus neutralizing antibodies, with or without co-admini

161 We demonstrate that vaccination induces virus-neutralizing antibodies without altering insulitis

162 Interestingly, virus-neutralizing antibodies worked synergistically wit